Diuretic Selection and Management

Introduction to Diuretic Therapy

The American College of Cardiology recommends that diuretics work by blocking sodium reabsorption at specific sites along the nephron, with their clinical utility directly determined by where they act and how much sodium they can excrete 1, 2

Loop diuretics (furosemide, bumetanide, torsemide) inhibit the Na+/K+/2Cl- cotransporter, blocking 20-25% of filtered sodium load and maintaining efficacy even with severe renal impairment, as stated by the American Heart Association 1, 3
Thiazide diuretics block sodium-chloride cotransporters, increasing fractional sodium excretion by only 5-10% of filtered load, but lose effectiveness when creatinine clearance falls below 40 mL/min, according to the American College of Cardiology 1, 3

For heart failure with fluid retention, the American Heart Association recommends loop diuretics (furosemide, torsemide, bumetanide) as the preferred first-line agents because they produce greater diuresis, work despite renal impairment, and have steep dose-response curves allowing escalation 1, 3, 4
In mild heart failure with preserved renal function, thiazide diuretics may be preferred when blood pressure control is equally important as volume management, as they provide more sustained antihypertensive effects, as stated by the American College of Cardiology 1, 4
For moderate to severe heart failure, loop diuretics are mandatory because thiazides lose efficacy with declining renal function and cannot adequately control volume overload, according to the American Heart Association 1, 3

The American College of Cardiology recommends that for hypertension, thiazide diuretics are first-line agents due to their long duration of action and proven cardiovascular mortality reduction 1, 4
For renal impairment (GFR <40 mL/min), loop diuretics maintain efficacy even with severely impaired renal function (GFR <30 mL/min), whereas thiazides become ineffective and must be replaced, as stated by the American Heart Association 1, 3
When using spironolactone in chronic kidney disease, serum potassium requires careful monitoring, according to the American College of Cardiology 2

Hypokalemia is the most common electrolyte abnormality with loop diuretic therapy, and hyponatremia occurs more frequently with thiazides than loop diuretics, as stated by the American Heart Association 2
The American College of Cardiology recommends checking serum electrolytes (sodium, potassium) 1-2 weeks after initiating diuretic therapy or changing doses 2

Diuretics should never be used alone in Stage C heart failure—they must be combined with ACE inhibitors/ARBs and beta-blockers to reduce clinical decompensation and improve long-term outcomes, as stated by the American Heart Association 1, 3
Inappropriately low diuretic doses cause fluid retention, diminishing ACE inhibitor response and increasing beta-blocker risk, according to the American College of Cardiology 3
Patients must avoid NSAIDs, which reduce diuretic efficacy and can precipitate acute kidney injury, as recommended by the American Heart Association 2